ACUTE MYOCARDIAL DYSFUNCTION ASSOCIATED WITH RITUXIMAB IN A PATIENT WITH SCHILDER-TYPE MULTIPLE SCLEROSIS: A CASE REPORT
DOI:
https://doi.org/10.56238/levv17n56-006Keywords:
Multiple Sclerosis, Rituximab, Cardiotoxicity, Monoclonal Antibodies, Case ReportAbstract
Introduction: Rituximab is an anti-CD20 monoclonal antibody widely used in the treatment of autoimmune and hematologic diseases, including off-label use in aggressive forms of multiple sclerosis. Although its overall safety profile is considered favorable, rare and potentially severe cardiovascular adverse events have been increasingly reported, particularly as its use expands beyond oncology settings.
Objective: To report a case of acute myocardial dysfunction temporally associated with rituximab infusion in a young patient with Schilder-type multiple sclerosis and no prior history of cardiac disease, and to discuss its clinical implications.
Methods: This is a case report based on a retrospective review of clinical, laboratory, electrocardiographic, and echocardiographic data obtained from the electronic medical record, complemented by a narrative review of the recent literature on anti-CD20–associated cardiotoxicity.
Case report: A 30-year-old female patient with Schilder-type multiple sclerosis developed sudden chest pain during rituximab infusion, associated with marked elevation of cardiac troponin levels and left ventricular systolic dysfunction documented by echocardiography. The infusion was immediately discontinued, and standard heart failure therapy was initiated, resulting in clinical improvement and recovery of cardiac function. Due to the adverse event, immunomodulatory therapy was subsequently changed.
Conclusion: This case suggests an association between rituximab use and acute myocardial dysfunction, even in young patients without traditional cardiovascular risk factors. It highlights the importance of early recognition of rare adverse events, appropriate monitoring during infusions, and multidisciplinary management to enhance the safety of immunobiological therapies.
Downloads
References
1. Alping, P., Frisell, T., Novakova, L., et al. (2023). Disease-modifying therapies in multiple sclerosis. Nature Reviews Neurology, 19(10), 635–651.
2. Langer-Gould, A., Bebo, B., & Cree, B. A. C. (2024). Rituximab for multiple sclerosis: Hiding in plain sight. Neurology, 102(19), Article e1835–e1837. DOI: https://doi.org/10.1212/WNL.0000000000208063
3. Salzer, J., Svenningsson, R., Alping, P., et al. (2016). Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy. Neurology, 87(20), 2074–2081. DOI: https://doi.org/10.1212/WNL.0000000000003331
4. Granqvist, M., Boremalm, M., Poorghobad, A., et al. (2018). Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurology, 75(3), 320–327. DOI: https://doi.org/10.1001/jamaneurol.2017.4011
5. Roos, I., Hughes, R., Zhao, Y., et al. (2023). Rituximab versus ocrelizumab in relapsing–remitting multiple sclerosis. JAMA Neurology, 80(7), 676–685.
6. Elgenidy, A., Abdelazeem, B., AlHefnawy, M., et al. (2024). Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 therapies: A systematic review and meta-analysis. Multiple Sclerosis and Related Disorders, 84, Article 105444. DOI: https://doi.org/10.3389/fneur.2024.1380654
7. Kimby, E. (2014). Tolerability and safety of rituximab. Blood, 123(13), 1948–1956.
8. Kridin, K., Mruwat, N., Weinstein, O., et al. (2023). Association of rituximab with risk of long-term cardiovascular and metabolic outcomes in patients with pemphigus. JAMA Dermatology, 159(1), 63–71. DOI: https://doi.org/10.1001/jamadermatol.2022.5182
9. Al-Yafeai, Z., Al-Badr, W., Alharthi, M., et al. (2022). Novel multiple sclerosis agents–associated cardiotoxicity: A pharmacovigilance study. International Journal of Cardiology, 364, 71–77. DOI: https://doi.org/10.22541/au.164873539.99715621/v2
10. Lyon, A. R., López-Fernández, T., Couch, L. S., et al. (2022). 2022 ESC Guidelines on cardio-oncology. European Heart Journal, 43(41), 4229–4361. DOI: https://doi.org/10.1093/eurheartj/ehac244
11. Tschöpe, C., Van Linthout, S., Spillmann, F., et al. (2021). Myocarditis and inflammatory cardiomyopathy: Current evidence and future directions. Nature Reviews Cardiology, 18(3), 169–193. DOI: https://doi.org/10.1038/s41569-020-00435-x
12. Bermea, K., Masson, R., Handzlik, M. K., et al. (2022). The role of B cells in cardiomyopathy and heart failure. Current Heart Failure Reports, 19(4), 173–186.
13. Hajjar, L. A., Costa, I. B. S., da Silva, E. A. B., et al. (2020). Brazilian cardio-oncology guideline – 2020. Arquivos Brasileiros de Cardiologia, 115(5), 1006–1043. DOI: https://doi.org/10.36660/abc.20201006
14. Farooq, M., Siddiqui, A., Khan, S., et al. (2021). Rituximab-associated cardiotoxicity: A pharmacovigilance study. Journal of Oncology Pharmacy Practice, 27(5), 1095–1101.
15. Keswani, A. N., Mohammad, A., Sykes, J. A., & Gaba, R. C. (2015). Rituximab-induced acute ST-elevation myocardial infarction. Case Reports in Oncological Medicine, 2015, Article 601098.
16. Ng, K. H., Dearden, C., & Gruber, P. C. (2015). Rituximab-induced Takotsubo syndrome: More cardiotoxic than it appears? BMJ Case Reports, 2015, Article bcr2014209070. DOI: https://doi.org/10.1136/bcr-2014-208203
17. Girkar, N., Zaki, S., & Kabadi, S. (2022). Reversible cardiomyopathy after rituximab treatment in a chronic lymphocytic leukemia patient. Journal of Pharmacy Practice, 35(5), 855–859.
18. Sharif, K., Watad, A., Bragazzi, N. L., et al. (2017). Anterior ST-elevation myocardial infarction induced by rituximab infusion: A case report and review of the literature. Journal of Clinical Pharmacy and Therapeutics, 42(3), 356–362. DOI: https://doi.org/10.1111/jcpt.12522
19. Ndukwu, P. O., Patel, A., Raza, S., et al. (2025). Rituximab-induced acute coronary syndrome. Cureus, 17(2), Article e78777. DOI: https://doi.org/10.7759/cureus.94202
20. Tschöpe, C., Van Linthout, S., Klein, O., et al. (2019). Targeting CD20+ B lymphocytes in inflammatory dilated cardiomyopathy with rituximab improves clinical course. European Heart Journal Case Reports, 3(3), Article ytz131. DOI: https://doi.org/10.1093/ehjcr/ytz131
21. Zhang, X., Zhang, Z., Zhuang, L., et al. (2022). Targeting B cells in cardiomyopathy and heart failure: Immunological mechanisms and therapeutic opportunities. Frontiers in Cardiovascular Medicine, 9, Article 869798.
22. Wattjes, M. P., Oreja-Guevara, C., Wuerfel, J., et al. (2024). Comparative safety profiles of ocrelizumab and rituximab in persons with multiple sclerosis. Annals of Neurology, 96(6), 919–929.
23. Fossum, I., Holmøy, T., Wergeland, S., et al. (2025). Early extended interval dosing of rituximab in multiple sclerosis: A prospective cohort study. Multiple Sclerosis and Related Disorders, 87, Article 105675. DOI: https://doi.org/10.1016/j.msard.2025.106400
24. Musigk, N., Sianis, M., & Tschöpe, C. (2024). The inflammatory spectrum of cardiomyopathies. Frontiers in Cardiovascular Medicine, 11, Article 1251780. DOI: https://doi.org/10.3389/fcvm.2024.1251780
25. Barbuti, E., De Luca, G., Signori, A., et al. (2025). A real-world multicenter study of ocrelizumab outcomes in multiple sclerosis. Multiple Sclerosis and Related Disorders, 90, Article 105859.
26. Min, A., & Win, K. L. Y. (2022). Takotsubo cardiomyopathy or hidden cardiotoxic event by rituximab. Clinical Medicine (London), 22(Suppl. 4), 18–19. DOI: https://doi.org/10.7861/clinmed.22-4-s18
27. Gupta, R. (2022). Takotsubo cardiomyopathy secondary to rituximab. American Journal of Therapeutics, 29(4), e469–e471. DOI: https://doi.org/10.1097/MJT.0000000000001239
28. Sheikh, M., Nugent, K., & Zaghla, H. (2015). Rituximab-induced left bundle branch block. Heart Views, 16(1), 25–27. DOI: https://doi.org/10.4103/1995-705X.152997
29. Cheungpasitporn, W., Kopecky, S. L., Specks, U., et al. (2017). Nonischemic cardiomyopathy after rituximab treatment for membranous nephropathy. Journal of Renal Injury Prevention, 6(1), 18–25. DOI: https://doi.org/10.15171/jrip.2017.04
30. Brili, S., Bei, E., Kounis, N. G., et al. (2021). Hypertensive crisis and pulmonary edema following rituximab-induced anaphylaxis. Acta Bio-Medica, 92(S1), Article e2021115.
31. Salem, J. E., Manouchehri, A., Moey, M., et al. (2020). Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational pharmacovigilance study. Lancet Oncology, 21(7), e358–e369.
